Gufic BioSciences Ltd

₹ 214 3.28%
25 Nov - close price
About

Gufic Biosciences Limited is engaged in the manufacture of pharmaceuticals, medicinal chemicals and botanical products.

Key Points

History[1]
Gufic was in the business of manufacturing and marketing injectable products since late 1970s. The group had earlier exited its API and formulations manufacturing division by selling its six major brands such as Mox (Amoxycillin) Injection, Zole (Miconazole Nitrate) etc. to Ranbaxy in 1997. The promoters then re-entered pharmaceutical formulations segment through incorporation of Gufic Biosciences Limited in 2000.
Gufic Biosciences has been manufacturing lyophilized injectables (their main business) for 40+ years. It started with small base of 50,000 vials back in 2007-08 to right now almost 4 million vials per month.

  • Market Cap 2,076 Cr.
  • Current Price 214
  • High / Low 290 / 170
  • Stock P/E 25.1
  • Book Value 31.9
  • Dividend Yield 0.05 %
  • ROCE 46.3 %
  • ROE 43.3 %
  • Face Value 1.00

Pros

  • Company has delivered good profit growth of 60.4% CAGR over last 5 years
  • Company has a good return on equity (ROE) track record: 3 Years ROE 34.2%
  • Debtor days have improved from 89.1 to 71.0 days.
  • Company's median sales growth is 22.5% of last 10 years
  • Company's working capital requirements have reduced from 82.6 days to 58.0 days

Cons

  • Company might be capitalizing the interest cost

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Figures in Rs. Crores

Sep 2019 Dec 2019 Mar 2020 Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022
86 98 87 54 128 167 132 251 194 172 162 165 175
76 86 75 55 99 139 108 205 158 139 131 132 142
Operating Profit 10 12 12 -1 29 27 24 46 36 33 32 33 33
OPM % 12% 12% 14% -1% 23% 16% 18% 18% 18% 19% 19% 20% 19%
2 3 1 1 2 0 1 1 0 2 0 0 1
Interest 4 3 4 3 4 4 3 1 2 1 1 1 2
Depreciation 3 2 4 2 5 3 4 4 4 4 4 4 5
Profit before tax 6 9 6 -5 23 20 17 42 30 29 26 28 27
Tax % 24% 25% 21% 27% 25% 24% 25% 25% 23% 27% 23% 26% 26%
Net Profit 4 7 5 -4 17 15 13 31 23 21 20 21 20
EPS in Rs 0.55 0.90 0.64 -0.48 2.23 1.99 1.65 3.22 2.41 2.17 2.09 2.17 2.08
Raw PDF

Profit & Loss

Figures in Rs. Crores

Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 TTM
69 81 98 121 148 201 245 306 351 379 488 779 674
63 74 87 109 134 181 222 267 305 327 404 633 544
Operating Profit 6 7 11 12 14 20 23 39 46 52 84 146 130
OPM % 9% 9% 11% 10% 10% 10% 9% 13% 13% 14% 17% 19% 19%
0 0 0 1 1 1 1 4 4 6 4 3 3
Interest 2 3 4 4 4 6 6 9 10 14 14 5 5
Depreciation 2 2 2 2 4 4 4 4 5 14 16 17 18
Profit before tax 2 3 5 6 7 10 14 30 35 30 58 127 110
Tax % 38% 49% 37% 32% 36% 29% 37% 45% 38% 25% 23% 24%
Net Profit 1 2 3 4 4 7 9 16 22 23 44 96 83
EPS in Rs 0.19 0.20 0.43 0.55 0.54 0.95 1.17 2.13 2.82 2.92 5.68 9.89 8.51
Dividend Payout % 27% 25% 12% 9% 9% 5% 4% 2% 2% 2% 2% 1%
Compounded Sales Growth
10 Years: 25%
5 Years: 26%
3 Years: 30%
TTM: -9%
Compounded Profit Growth
10 Years: 51%
5 Years: 60%
3 Years: 64%
TTM: 0%
Stock Price CAGR
10 Years: 42%
5 Years: 17%
3 Years: 46%
1 Year: 17%
Return on Equity
10 Years: 32%
5 Years: 34%
3 Years: 34%
Last Year: 43%

Balance Sheet

Figures in Rs. Crores

Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Sep 2022
8 8 8 8 8 8 8 8 8 10 10 10 10
Reserves 11 12 15 18 19 26 30 46 68 120 164 259 300
19 20 35 33 33 43 57 80 98 126 62 64 185
23 34 32 52 67 75 84 104 106 152 157 188 200
Total Liabilities 61 74 90 111 127 152 178 238 280 408 392 521 695
17 18 27 30 25 22 22 23 24 83 100 115 123
CWIP 0 1 3 0 0 0 0 2 10 31 13 41 62
Investments 0 0 0 0 0 0 0 0 0 0 0 0 1
43 55 60 81 102 130 156 213 245 294 279 365 509
Total Assets 61 74 90 111 127 152 178 238 280 408 392 521 695

Cash Flows

Figures in Rs. Crores

Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
1 5 5 11 11 -4 -4 -5 5 47 87 104
-2 -3 -13 -3 -2 -1 -5 -9 -13 -43 -7 -96
1 -2 8 -7 -5 5 7 14 8 -4 -79 -3
Net Cash Flow -0 0 0 1 4 -0 -1 1 -0 0 2 5

Ratios

Figures in Rs. Crores

Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Debtor Days 93 101 75 85 82 102 78 97 107 103 93 71
Inventory Days 126 137 143 144 165 180 190 238 190 249 138 102
Days Payable 145 180 144 176 223 188 132 192 157 238 162 125
Cash Conversion Cycle 74 58 74 54 25 94 136 143 141 114 69 48
Working Capital Days 96 82 71 64 48 76 84 109 128 110 80 58
ROCE % 13% 15% 18% 17% 18% 24% 24% 33% 30% 21% 29% 46%

Shareholding Pattern

Numbers in percentages

Dec 2019 Mar 2020 Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022
65.75 65.75 65.75 65.75 65.75 65.75 65.13 75.48 75.48 75.48 75.00 75.00
1.00 0.59 0.59 0.06 0.33 0.23 0.14 1.52 1.69 1.51 1.38 0.06
8.97 8.93 7.99 8.73 8.71 8.24 3.24 2.13 1.19 1.12 1.13 1.16
24.28 24.73 25.67 25.46 25.21 25.77 31.49 20.87 21.64 21.89 22.49 23.76

Documents

Concalls